Suchergebnisse - "Olsson, Daniel"

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    Quelle: Pharmacoepidemiology & Drug Safety; Oct2023 Supplement 1, Vol. 32, p643-675, 33p

  10. 10

    Weitere Verfasser: Arlien-Søborg, Mai C. Dal, Jakob Heck, Ansgar et al.

    Dateibeschreibung: application/pdf

    Relation: Jens Otto Lunde J\u00F8rgensen and Jakob Dal have received unrestricted research grants and lecture fees from Pfizer and IPSEN. Mai C. Arlien\u2010S\u00F8borg has received lecture fees from Pfizer. Daniel Olsson has served as a consultant for Ipsen, Pfizer, Novo Nordisk, and Sandoz; has received research grants from Sandoz and Pfizer; and is an employee at AstraZeneca as of 30 August 2021. This work was supported by an unrestricted research grant from Pfizer. The other authors declare no conflict of interest.; http://hdl.handle.net/10138/585324; 85195918201; 001244261400001

  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20